The comparative effects of phenylbutazone and G27202 (metabolite i) in patients with rheumatoid arthritis: An assessment of methods for antirheumatic drug evaluation

The effects of phenylbutazone and its metabolite, MI, on certain manifestations of rheumatoid arthritis were studied in 24 patients by a double‐blind method. Grip strength and the duration of morning stiffness were influenced significantly by both the parent drug and its derivative. By such partially subjective criteria the metabolite MI had greater antirheumatic activity than phenylbutazone. Sedimentation rates and joint swelling (circumference) were not altered appreciably by either agent. Le effectos de phenylbutazona e de su metabolite MI super certe manifestationes de arthritis rheumatoide esseva studiate in 24 patientes per medio de un methodo bis‐occulte. Le fortia del stringer manual e le duration del rigiditate matinal esseva influentiate de maniera significative tanto per le droga mesme como etiam per su metabolito. Secundo iste criterios de character partialmente subjective, MI habeva un plus grande activitate antirheumatic que phenylbutazona. Le sedimentation erythrocytic e le tumescentia articular non esseva alterate appreciabilemente per le un o le altere agente.